Isamu Okamoto (I Okamoto)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 22

Top Topics

Idiopathic Pulmonary Fibrosis

Tyrosine Kinase

Small Cell Lung Cancer

Top Venues

Scandinavian journal of rheumatology

This page only lists publications with an associated author ORCID identifier.

Publications

Masahiro Ayano, Kazuya Tsubouchi, K Suzuki, Yasutaka Kimoto, Yojiro Arinobu, Koichi Akashi, Takahiko Horiuchi, Isamu Okamoto, Hiroaki Niiro
Comparing the safety and efficacy of nintedanib starting dose in patients with connective tissue disease-associated interstitial lung diseases. Scandinavian journal of rheumatology 53 (4) (2024)
Masahiro Ayano, Kazuya Tsubouchi, K Suzuki, Yasutaka Kimoto, Yojiro Arinobu, Koichi Akashi, Takahiko Horiuchi, Isamu Okamoto, Hiroaki Niiro
Comparing the safety and efficacy of nintedanib starting dose in patients with connective tissue disease-associated interstitial lung diseases. Scandinavian journal of rheumatology (2024)
Kazuya Tsubouchi, Naoki Hamada, Shoji Tokunaga, Katsuyuki Ichiki, Shohei Takata, Hiroshi Ishii, Yasuhiko Kitasato, Masaki Okamoto, Satoru Kawakami, Kazuhiro Yatera, Masayuki Kawasaki, Masaki Fujita, Makoto Yoshida, Takashige Maeyama, Taishi Harada, Hiroshi Wataya, Ryo Torii, Masashi Komori, Yuichi Mizuta, Kazunori Tobino, Eiji Harada, Hidetake Yabuuchi, Yoichi Nakanishi, Isamu Okamoto
Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registry. BMJ open respiratory research 10 (1) (2023)
Jhanelle E Gray, Myung-Ju Ahn, Geoffrey R Oxnard, Frances A Shepherd, Fumio Imamura, Ying Cheng, Isamu Okamoto, Byoung Chul Cho, Meng-Chih Lin, Yi-Long Wu, Margarita Majem Tarruella, Oliver Gautschi, Michael J Boyer, Krishna C Bulusu, Aleksandra A Markovets, J Carl Barrett, Rachel Hodge, Astrid McKeown, Ryan J Hartmaier, Juliann Chmielecki, Vassiliki A Papadimitrakopoulou, Suresh R Ramalingam
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Akito Hata, Isamu Okamoto, Naoki Inui, Morihito Okada, Masahiro Morise, Kohei Akiyoshi, Masayuki Takeda, Yasutaka Watanabe, Shunichi Sugawara, Naofumi Shinagawa, Kaoru Kubota, Toshiaki Saeki, Tomohide Tamura
Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Hirohito Tada, Tetsuya Mitsudomi, Toshihiro Misumi, Kenji Sugio, Masahiro Tsuboi, Isamu Okamoto, Yasuo Iwamoto, Noriaki Sakakura, Shunichi Sugawara, Shinji Atagi, Toshiaki Takahashi, Hidetoshi Hayashi, Morihito Okada, Hidetoshi Inokawa, Hiroshige Yoshioka, Kazuhisa Takahashi, Masahiko Higashiyama, Ichiro Yoshino, Kazuhiko Nakagawa, null null
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT). Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Miyako Satouchi, Kaname Nosaki, Toshiaki Takahashi, Kazuhiko Nakagawa, Keisuke Aoe, Takayasu Kurata, Akimasa Sekine, Atsushi Horiike, Tatsuro Fukuhara, Shunichi Sugawara, Shigeki Umemura, Hideo Saka, Isamu Okamoto, Nobuyuki Yamamoto, Hiroshi Sakai, Kazuma Kishi, Nobuyuki Katakami, Hidehito Horinouchi, Toyoaki Hida, Hiroaki Okamoto, Shinji Atagi, Tatsuo Ohira, Shi Rong Han, Kazuo Noguchi, Victoria Ebiana, Katsuyuki Hotta
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset. Cancer science 112 (12) (2021)
Yasuto Yoneshima, Koji Kato, Haruna Minami, Munehiko Ikeda, Hiroyuki Watanabe, Goichi Yoshimoto, Toshihiro Miyamoto, Koichi Akashi, Yoichi Nakanishi, Isamu Okamoto
HTLV-1 seropositive patients with lung cancer treated with PD-1 inhibitors. Cancer science 111 (9) (2020)
Takayuki Takahama, Koichi Azuma, Mototsugu Shimokawa, Masayuki Takeda, Hidenobu Ishii, Terufumi Kato, Haruhiro Saito, Haruko Daga, Yuko Tsuboguchi, Isamu Okamoto, Kohei Otsubo, Hiroaki Akamatsu, Shunsuke Teraoka, Toshiaki Takahashi, Akira Ono, Tatsuo Ohira, Toshihide Yokoyama, Kazuko Sakai, Nobuyuki Yamamoto, Kazuto Nishio, Kazuhiko Nakagawa
Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study. Cancer 126 (9) (2020)
Nobuhisa Ando, Kentaro Tanaka, Kohei Otsubo, Gouji Toyokawa, Yuki Ikematsu, Maako Ide, Yasuto Yoneshima, Eiji Iwama, Hiroyuki Inoue, Kayo Ijichi, Tetsuzo Tagawa, Yoichi Nakanishi, Isamu Okamoto
Association of Mps one binder kinase activator 1 (MOB1) expression with poor disease-free survival in individuals with non-small cell lung cancer. Thoracic cancer 11 (10) (2020)
Kaoru Tanaka, Satoshi Morita, Masahiko Ando, Takuma Yokoyama, Atsushi Nakamura, Hiroshige Yoshioka, Takashi Ishiguro, Satoru Miura, Ryo Toyozawa, Tetsuya Oguri, Haruko Daga, Ryo Ko, Akihiro Bessho, Motoko Tachihara, Yasuo Iwamoto, Katsuya Hirano, Yoichi Nakanishi, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Isamu Okamoto
A randomized phase 3 study of maintenance therapy with S-1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L). Cancer 126 (16) (2020)
Miyako Satouchi, Kaname Nosaki, Toshiaki Takahashi, Kazuhiko Nakagawa, Keisuke Aoe, Takayasu Kurata, Akimasa Sekine, Atsushi Horiike, Tatsuro Fukuhara, Shunichi Sugawara, Shigeki Umemura, Hideo Saka, Isamu Okamoto, Nobuyuki Yamamoto, Hiroshi Sakai, Kazuma Kishi, Nobuyuki Katakami, Hidehito Horinouchi, Toyoaki Hida, Hiroaki Okamoto, Shinji Atagi, Tatsuo Ohira, Shi Rong Han, Kazuo Noguchi, Victoria Ebiana, Katsuyuki Hotta
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset. Cancer science 111 (12) (2020)
Ikuo Sekine, Yasushi Shintani, Takehito Shukuya, Koichi Takayama, Akira Inoue, Isamu Okamoto, Katsuyuki Kiura, Kazuhisa Takahashi, Hirotoshi Dosaka-Akita, Yuichi Takiguchi, Etsuo Miyaoka, Meinoshin Okumura, Ichiro Yoshino
A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients. Cancer science 111 (5) (2020)
Kohei Otsubo, Eiji Iwama, Kayo Ijichi, Naoki Kubo, Yasuto Yoneshima, Hiroyuki Inoue, Kentaro Tanaka, Atsushi Osoegawa, Tetsuzo Tagawa, Yoichi Nakanishi, Isamu Okamoto
Paired genetic analysis by next-generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis. Cancer science 111 (7) (2020)
Tomonori Hirashima, Miyako Satouchi, Toyoaki Hida, Makoto Nishio, Terufumi Kato, Hiroshi Sakai, Fumio Imamura, Katsuyuki Kiura, Isamu Okamoto, Kazuo Kasahara, Hirohiko Uchida, Sarah L Vowler, Tetsuya Mitsudomi
Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis. Cancer science 110 (9) (2019)
Eiji Iwama, Yasushi Goto, Haruyasu Murakami, Shinsuke Tsumura, Hiroyuki Sakashita, Yoshiaki Mori, Noriaki Nakagaki, Yuka Fujita, Masahiro Seike, Akihiro Bessho, Manabu Ono, Masaru Nishitsuji, Hiroaki Akamatsu, Ryotaro Morinaga, Takanori Akagi, Takayuki Shimose, Shoji Tokunaga, Nobuyuki Yamamoto, Yoichi Nakanishi, Kenji Sugio, Isamu Okamoto
Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401. The oncologist 25 (4) (2019)
Isamu Okamoto, Kazuko Sakai, Masafumi Takeshita, Daijiro Harada, Koichi Azuma, Keiichi Ota, Hiroaki Akamatsu, Koichi Goto, Atsushi Horiike, Takayasu Kurata, Noriaki Nakagaki, Kaname Nosaki, Eiji Iwama, Yoichi Nakanishi, Kazuto Nishio, Isamu Okamoto
Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA. The oncologist 24 (8) (2019)
Yuko Tsuchiya-Kawano, Tomonari Sasaki, Hiroyuki Yamaguchi, Katsuya Hirano, Atsushi Horiike, Miyako Satouchi, Shinobu Hosokawa, Ryotaro Morinaga, Kazutoshi Komiya, Koji Inoue, Yuka Fujita, Ryo Toyozawa, Tomoki Kimura, Kosuke Takahashi, Kazuo Nishikawa, Junji Kishimoto, Yoichi Nakanishi, Isamu Okamoto
Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer. The oncologist 25 (6) (2019)
Eiji Iwama, Kazuko Sakai, Noriko Hidaka, Koji Inoue, Akiko Fujii, Noriaki Nakagaki, Keiichi Ota, Ryo Toyozawa, Koichi Azuma, Keita Nakatomi, Taishi Harada, Junko Hisasue, Shinya Sakata, Takayuki Shimose, Junji Kishimoto, Yoichi Nakanishi, Kazuto Nishio, Isamu Okamoto
Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors. Cancer 126 (1) (2019)
Katsuyuki Kiura, Kiyotaka Yoh, Nobuyuki Katakami, Naoyuki Nogami, Kazuo Kasahara, Toshiaki Takahashi, Isamu Okamoto, Mireille Cantarini, Rachel Hodge, Hirohiko Uchida
Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples. Cancer science 109 (4) (2018)
Eiji Iwama, Kazuko Sakai, Koichi Azuma, Daijiro Harada, Kaname Nosaki, Katsuyuki Hotta, Makoto Nishio, Takayasu Kurata, Tatsuro Fukuhara, Hiroaki Akamatsu, Koichi Goto, Takayuki Shimose, Junji Kishimoto, Yoichi Nakanishi, Kazuto Nishio, Isamu Okamoto
Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing. Cancer science 109 (12) (2018)
Maako Ide, Kentaro Tanaka, Shunya Sunami, Tatsuma Asoh, Takashige Maeyama, Nobuko Tsuruta, Yoichi Nakanishi, Isamu Okamoto
Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis. Thoracic cancer 9 (11) (2018)